With tirzepatide, plateaus tend to occur later, often around months 9-12, and at higher absolute weight loss levels
Although GLP-1RA are improving the lives of patients affected by type 2 diabetes or the metabolic syndrome (196), the physiology of GLP-1 is far from being clear
The gut and beyond: GI effects and other tissues In the gastrointestinal tract, the receptor appears in the Brunners glands of the duodenum, in parietal cells, and in gastric smooth muscle, where it slows gastric emptying
Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets
Both produce significantly greater weight loss than liraglutide, require only weekly injections, and are approved by NICE for weight management